THE BELGIAN OPHTHALMIC ASSOCIATIONS
View abstract
This abstract is assigned to session Poster session
| Title | Efficacy and tolerability of bimatoprost 0.1 mg/ml (Lumigan®) in POAG/OHT in routine clinical practice in Belgium |
| Abstract Nr. | P119 |
| Purpose | Observational study to assess the efficacy, tolerability and persistence of use of bimatoprost 0.1 mg/ml in patients with POAG or OHT) in routine clinical practice. |
| Methods | Patients with POAG or OHT prescribed bimatoprost 0.1 mg/ml were enrolled. Disease characteristics and prior treatments were collected at baseline. Intraocular pressure (IOP), adverse events (AEs) and discontinuations were recorded prospectively. Data were analysed descriptively |
| Results | A total of 933 patients from 117 centres in Belgium were included; median age 65.8 years and 51% females. Most patients had POAG (64%) and 52% of patients had previously received IOP-lowering medication. The median duration of therapy was 8.9 weeks. Mean IOP was reduced from baseline to final visit by 23% in both eyes: by -5.1 mmHg in the right eye (from 22.0 to 16.9 mmHg) and by -5.0 mmHg in the left eye (from 22.0 to 17.0 mmHg). According to physician evaluation, target IOP was reached or even lower in 75.9% of patients and tolerability was very good or good in 87.9% of patients. The majority of patients (80.9%) indicated they would continue bimatoprost beyond the end of the study. AEs were reported in 142 patients (15.2%). Only hyperaemia (7.6%), eye irritation (2.7%) and eye pain (1.5%) occurred in >1% of patients. |
| Conclusion | Bimatoprost 0.1 mg/ml can produce additional IOP-lowering in routine clinical practice in patients with POAG or OHT who have had prior therapy, as well as reducing IOP in previously-untreated patients. Bimatoprost 0.1 mg/ml was well tolerated and effective and was associated with a high rate of continuation of therapy. |
Authors 1
| Last name | STEVENS |
| Initials | AM |
| Department | Dept Ophthalmology University Clinic |
| City | Ghent |
Authors 2
| Last name | Hondegem |
| Initials | K |
| Department | Middelheimziekenhuis Ophtalmologie |
| City | Antwerpen |
Authors 3
| Last name | Deghislage |
| Initials | C |
| Department | Ziekenhuis Oost-Limburg Oogziekten |
| City | Genk |
Authors 4
| Last name | Morgan-Warren |
| Initials | R |
| Department | Allergan UK |
Authors 5
| Last name | Leaback |
| Initials | R |
| Department | Allergan UK |